Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H13NO3 |
Molecular Weight | 207.2258 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(=C1)N2CC(CO)OC2=O
InChI
InChIKey=MXUNKHLAEDCYJL-UHFFFAOYSA-N
InChI=1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3
Molecular Formula | C11H13NO3 |
Molecular Weight | 207.2258 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
CNS Activity
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. | 1990 Dec |
|
The clinical pharmacology of depressive states. | 2002 Mar |
|
3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. | 2002 Mar 14 |
|
Highly efficient CuI-catalyzed coupling of aryl bromides with oxazolidinones using Buchwald's protocol: a short route to linezolid and toloxatone. | 2003 Apr 3 |
|
Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. | 2003 Mar |
|
A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. | 2003 Oct |
|
Neuroendocrine predictors of the evolution of depression. | 2005 |
|
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood. | 2007 May |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Analysis of activity and inhibition of oxygen-dependent enzymes by optical respirometry on the LightCycler system. | 2010 Feb 15 |
|
Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones. | 2011 Dec 8 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Daily toloxatone dose was standardized in a 400 mg intake. https://www.ncbi.nlm.nih.gov/pubmed/1843597
Adult : PO 200 mg 3 times/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24698
The kinetics of MAO inhibition in vitro with rat brain
stem (an area containing mostly type A MAO activity,) were measured with 14C-5-HT as substrate. MAO activity was non-competitively inhibited
(maximal velocity was decreased by 80 %) by toloxatone
(10uM), with apparent Ki value of 4.8 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:56:47 GMT 2023
by
admin
on
Fri Dec 15 16:56:47 GMT 2023
|
Record UNII |
5T206015T5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N06AG03
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
||
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
||
|
WHO-VATC |
QN06AG03
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09245
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
134870
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
C97715
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
100000077761
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
34521
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
3429
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
249-522-2
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
C010798
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
2702
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
TOLOXATONE
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
5T206015T5
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
29218-27-7
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
m10950
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID40865478
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
SUB11169MIG
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | |||
|
38382
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL18116
Created by
admin on Fri Dec 15 16:56:47 GMT 2023 , Edited by admin on Fri Dec 15 16:56:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |